Paul Spittle: A time of 'change' and 'humility'

March 21, 2016 BioPharmaDispatch Executive

This is a preview of subscriber content

Subscribe now to continue reading.

AstraZeneca could launch up to 25 new molecular entities between 2015 and 2020, according to the manager director of is Australian business, Paul Spittle. …

Subscribe now to continue reading.

Latest Video

New Stories

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 12, 2025 - - Latest News
Rare Cancers Australia says election is the chance to end the ‘cancer lottery’
February 12, 2025 - - Latest News
Specialised Therapeutics announces Thai approval of breast cancer therapy
February 12, 2025 - - Latest News
Merck adds experienced industry executive to leadership team
February 11, 2025 - - Latest News
Sandoz summit promotes reform to boost the use of biosimilars
February 11, 2025 - - Latest News
AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025 - - Latest News
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 - - Latest News

Paul Spittle: A time of 'change' and 'humility'

This is a preview of subscriber content

Latest Video

Most Read

Historical change on pharmacy prescribing could be a sign of more to come

Victorian official appointed to HTA Review implementation advisory group

'Unfortunately, there remain significant gaps in knowledge among healthcare professionals when it comes to menopause'

Proponents of meaningful reform might consider pharmacy prescribing as a case study

Sandoz summit promotes reform to boost the use of biosimilars

New Stories

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus

Rare Cancers Australia says election is the chance to end the ‘cancer lottery’

Specialised Therapeutics announces Thai approval of breast cancer therapy

Merck adds experienced industry executive to leadership team

Sandoz summit promotes reform to boost the use of biosimilars

AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus

Sign In

Paul Spittle: A time of 'change' and 'humility'

This is a preview of subscriber content

Latest Video

Most Read

Historical change on pharmacy prescribing could be a sign of more to come

Victorian official appointed to HTA Review implementation advisory group

'Unfortunately, there remain significant gaps in knowledge among healthcare professionals when it comes to menopause'

Proponents of meaningful reform might consider pharmacy prescribing as a case study

Sandoz summit promotes reform to boost the use of biosimilars

Follow Us

New Stories

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus

Rare Cancers Australia says election is the chance to end the ‘cancer lottery’

Specialised Therapeutics announces Thai approval of breast cancer therapy

Merck adds experienced industry executive to leadership team

Sandoz summit promotes reform to boost the use of biosimilars

AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus